In advanced diabetic retinopathy, 1 of 22 octreotide-treated eyes versus 9 of 24 control eyes required PRP; independent-event analysis gave P < 0.006.
In plain wordsIn advanced diabetic retinopathy, 1 of 22 eyes with octreotide versus 9 of 24 control eyes required laser treatment.
- Peptide
- Octreotide
- Outcome
- DecreaseHigh-risk retinopathy requiring photocoagulation
- Study
n: not reported in source
- Comparator
- Conventional diabetes management
- Outcome group
- Vision and retina · Eye
- Studied dose
- 200-5,000 microg/day · subcutaneousAs given in this study (human).
Measurements
- Eyes reaching high-risk PDR requiring PRP
- 1 eyes
- octreotide arm, of 22
- Eyes requiring PRP
- 9 eyes
- control arm, of 24
Source sentences
Only 1 of 22 eyes from patients treated with octreotide reached high-risk PDR requiring PRP, compared with control patients, in whom 9 of 24 eyes required PRP.
3 context sentences(design, population, supporting numbers)
The decreased incidence of progression requiring laser surgery was statistically significant if events were considered independently (P < 0.006).
Patients with severe nonproliferative DR (NPDR) or early non-high-risk proliferative DR (PDR) were randomly assigned to conventional diabetes management (control group, 12 patients) or to treatment with maximally tolerated doses of octreotide (200-5,000 microg/day subcutaneously; 11 patients).
Ocular changes in each eye were assessed at a minimum of every 3 months for 15 months or until disease progressed to high-risk PDR requiring laser surgery.